KR101590858B1 - Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof - Google Patents
Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof Download PDFInfo
- Publication number
- KR101590858B1 KR101590858B1 KR1020140019506A KR20140019506A KR101590858B1 KR 101590858 B1 KR101590858 B1 KR 101590858B1 KR 1020140019506 A KR1020140019506 A KR 1020140019506A KR 20140019506 A KR20140019506 A KR 20140019506A KR 101590858 B1 KR101590858 B1 KR 101590858B1
- Authority
- KR
- South Korea
- Prior art keywords
- red bean
- bean powder
- weight
- juice
- powder
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 73
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 17
- 235000015203 fruit juice Nutrition 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 title description 4
- 235000006089 Phaseolus angularis Nutrition 0.000 title 1
- 240000007098 Vigna angularis Species 0.000 title 1
- 235000010711 Vigna angularis Nutrition 0.000 title 1
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 116
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 116
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 239000004310 lactic acid Substances 0.000 claims abstract description 8
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
- 229960002675 xylitol Drugs 0.000 claims abstract description 6
- 235000010447 xylitol Nutrition 0.000 claims abstract description 6
- 239000000811 xylitol Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 9
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 9
- 244000298697 Actinidia deliciosa Species 0.000 claims description 7
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 7
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 7
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 7
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 7
- 235000021014 blueberries Nutrition 0.000 claims description 7
- 240000008790 Musa x paradisiaca Species 0.000 claims description 6
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 abstract description 20
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 4
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 235000012041 food component Nutrition 0.000 abstract description 2
- 230000002965 anti-thrombogenic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 239000002034 butanolic fraction Substances 0.000 description 7
- 239000002038 ethyl acetate fraction Substances 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 238000007711 solidification Methods 0.000 description 5
- 230000008023 solidification Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 235000009434 Actinidia chinensis Nutrition 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 241001107116 Castanospermum australe Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000021279 black bean Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000030999 Monascus pilosus Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000039850 Vigna nakashimae Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019587 texture Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6422—Xylitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 천연과즙 및 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말 및 그 제조방법의 제공을 목적으로 하며, 삶은 팥 분말, 자일리톨, 유산균분말의 혼합물에 바나나과즙, 퀴위과즙 및 블루베리과즙을 배합하고 과립화 및 건조하는 것으로 이루어진다.
본 발명의 천연과즙 및 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말은 가공함으로써 섭취가 간편한 특징이 있고 또 팥과 천연과즙의 영양성분의 조합 및 우수한 항혈전 활성에 의해 심혈관계, 뇌혈관계 질환의 예방 및 개선에 유용한 건강보조식품으로 제공하는 것이다.The present invention provides an anti-thrombocyte activated granule type red bean powder using natural fruit juice and red bean powder and a method for preparing the same. The present invention also relates to a method for producing a granular red bean powder, which comprises a mixture of boiled red bean powder, xylitol and lactic acid bacterium powder, Followed by granulation and drying.
The granular red bean powder having enhanced anti-thrombogenic activity using the natural juice and red bean powder of the present invention is characterized by being easy to ingest by processing. Also, the combination of nutritional components of red bean and natural fruit juice and excellent antithrombotic activity are effective in preventing cardiovascular diseases, cerebrovascular diseases Which is useful for prevention and improvement of the health food.
Description
본 발명은 천연과즙 및 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말 및 그 제조방법에 관한 것이다.The present invention relates to granular red bean powder enhanced in antithrombotic activity using natural fruit juice and red bean powder, and a method for producing the same.
팥은 예로부터 중국, 한국, 일본 등 동양의 온대지방에서 주로 재배되어 온 콩과의 일년초 식물로서, 팥은 각기병에 좋은 식품으로 알려져 왔으며, 속이 열한 것과 소갈을 다스리는 식품으로 알려져 있으며, 명의별록에는 팥은 한열과 속이 열한 것을 다스리며 소명을 이롭게 하고 소갈에도 좋다고 되어있고, 약성본초에는 팥은 열독을 다스리고 악혈을 없애고 또 비와 위를 튼튼하게 해준다고 기록되어있다.Red bean is an annual plant of soybean which has been cultivated mainly in the temperate regions of East Asia such as China, Korea and Japan. Red bean has been known as a good food for each disease, It is said that the red bean regulates the fever and the twelfth, and it is said that it is beneficial to the calling and to the frog, and the red bean is in the weakly acidic herb, and it is said that it regulates the fever, eliminates the bloodsiness and strengthens the rain and stomach.
특히, 팥에는 비타민B1이 아주 많이 들어 있으므로 비타민B1의 부족과 관련된 식욕부진, 피로감, 수면장애, 기억력감퇴, 신경쇠약 등의 증세 및 질병의 예방과 퇴치에 유용하며, 신경을 많이 쓰는 정신근로자나 수험생 등에게 좋은 식품이며 또 신장병, 당뇨병 등에도 유효하다.Especially, because red bean contains a lot of vitamin B1, it is useful for prevention and elimination of symptoms such as anorexia, fatigue, sleeping disorder, memory loss, nervous breakdown and diseases associated with the lack of vitamin B1, It is a good food for examinees and is also effective for kidney disease, diabetes and the like.
최근 민간요법이나 논문 등에 의해 팥의 기능이 밝혀지면서 새로운 well-being 제품으로 서서히 두각을 나타내고 있어, 향후 그 판매량이 증가할 것으로 기대되지만 가공 공정상의 어려움으로 인하여 다양한 제품으로 출시되지 못하고 있으므로 대중적으로 큰 호응을 유도하지는 못하고 있다.As the function of red beans has recently been revealed by folk remedies and papers, it is gradually emerging as a new well-being product, and it is expected that the sales volume will increase in the future. However, due to difficulties in processing, It does not induce a response.
일반적으로 팥은 잡곡밥, 팥죽, 빵류 등에 사용하는 팥앙금(팥소), 양갱 등에 주로 이용되고 있으며, 건강식품 및 의약과 관련한 선행기술로 예를 들면, 국내 등록특허공보 등록번호 10-1067611호에 건강식품으로 팥을 삶은 물에 양조식초를 첨가하고, 검은콩을 혼합한 슬러리 상태의 분쇄물에 1 ~ 2중량%로 팥앙금을 첨가 혼합하여 가열 살균처리한 다음 용기에 충전하는 팥 음료의 제조방법을 개시하고 있고, 국내특허공보 등록번호 10-1166698호에는 좀돌팥(Vigna nakashimae)의 종실을 분쇄하여 종실무게 10 ~ 20배의 50 ~ 100% 에탄올 수용액으로 20 ~ 30℃에서 교반하여 추출하는 단계, 상기 추출액을 원심분리하여 상등액 만을 회수하는 단계 및 상기 액을 감압 농축 및 동결건조시켜 연갈색 또는 갈색의 분말을 제조하는 단계를 포함하는 알파-글루코시데이즈 억제 효과를 갖는 좀돌팥 추출물의 제조방법 및 당뇨병 또는 비만의 예방 및 치료용 조성물을 개시하고 있으며, 국내 등록특허공보 등록번호 10-1001705호에는 팥 0.87 내지 8.7 중량부, 흑태 0.355 내지 3.55 중량부, 할맥 6.705 내지 67.05 중량부, 찰보리쌀 1.315 내지 13.15 중량부, 현미 5.735 내지 57.35중량부, 찹쌀 8.96 내지 89.6 중량부 및 찰흑미 3.735 내지 37.35 중량부를 포함하여 이루어지는 비만, 고지혈증 및 당뇨의 예방 및 개선용 조성물을 개시하고 있으며, 또 국내 등록특허공보 등록번호 10-1249795호에는 홍국균을 포함하는 고체 종균으로 팥을 발효시켜 얻은 산물이고 발효에 의해 발효 전보다 향상된 항산화 활성및 콜레스테롤 저하 활성을 나타내는 발효 팥으로서, 상기 고체 종균은 고체 배지인 밀 기울 또는 쌀겨에 모나스커스 필로서스(Monascus pilosus) 홍국균 또는 이를 포함하는 종균용 배양액을 접종하고 배양하여 수득한 것을 특징으로 하는 발효 팥 및 항산화용 조성물을 개시하고 있다.Generally, red beans are mainly used in bean jam (bean jam), rice bran, etc. used for rice, rice porridge, and bakery products. Prior art related to health foods and medicines include, for example, Korean Patent Registration No. 10-1067611, Discloses a process for preparing red bean beverages in which brewed vinegar is added to boiled water, black beans are mixed with 1 to 2 wt% of bean jam in a slurry state mixed with the black beans, , And Korean Patent Publication No. 10-1166698 discloses a method of pulverizing seeds of Vigna nakashimae and extracting it by stirring at 20 to 30 ° C in an aqueous 50 to 100% ethanol solution having a seed weight of 10 to 20 times, Centrifuging the extract to recover only the supernatant, and concentrating the supernatant and lyophilizing the solution to prepare a light brown or brown powder. The alpha-glucosidase inhibitory effect And a composition for prevention and treatment of diabetes or obesity is disclosed in Korean Patent Registration No. 10-1001705. The composition includes 0.87 to 8.7 parts by weight of red bean, 0.355 to 3.55 parts by weight of black bean, Discloses a composition for prevention and improvement of obesity, hyperlipidemia and diabetes, which comprises 67.05 parts by weight of pearl rice, 1.315 to 13.15 parts by weight of pearl rice, 5.735 to 57.35 parts by weight of brown rice, 8.96 to 89.6 parts by weight of glutinous rice, and 3.735 to 37.35 parts by weight of black rice In addition, Korean Registered Patent Publication No. 10-1249795 discloses a fermented red bean which is a product obtained by fermenting red beans with a solid germ including red ginseng root and exhibiting an antioxidative activity and a cholesterol lowering activity improved by fermentation before fermentation, Monascus pilosus in wheat or rice bran, solid medium, A seed culture comprising inoculation and the culture to initiate the fermentation and the beans antioxidant composition, wherein the resultant.
본 발명은 상기한 선행기술에 비하여 제조공정이 간단하고, 영양소 및 기능성과 함께 항혈전 활성이 강화된 천연과즙 및 팥을 주재로 한 과립형 건강보조식품을 제조함으로써 본 발명을 완성하였다.The present invention has been accomplished by preparing granular health supplements based on natural juice and red bean having a simple manufacturing process, enhanced nutritional and functional properties, and enhanced antithrombotic activity as compared with the prior art described above.
본 발명은 천연과즙 및 팥분말을 이용하여 항혈전 활성이 강화된 과립형 팥분말을 제조하는 방법의 제공을 목적으로 하며, 구체적으로는 팥은 저장성이 좋으나, 가공을 위해 삶을 경우 최대한 빨리 섭취해야 하는 결점을 개선하고 섭취가 간편하고, 영양소 및 기능성을 개선하여 항혈전 활성이 강화된 천연과즙 및 팥분말을 이용한 과립형 팥분말의 제조방법 및 그 제조방법에 의해 제조된 항혈전 활성이 강화된 과립형 팥분말로 이루어진 건강식품의 제공을 목적으로 하는 것이다.The present invention aims to provide a method for preparing granular red bean powder having enhanced antithrombotic activity by using natural juice and red bean powder. Specifically, red bean is good in storage property, but when taken for processing, A method for preparing granular red bean powder using natural juice and red bean powder with improved antioxidant activity by improving deficiencies and improving nutrients and functionalities and improving the antithrombotic activity produced by the method The present invention also provides a health food comprising the granular red bean powder.
본 발명의 목적을 달성하기 위한 과제의 해결수단으로 천연과즙 및 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말의 제조방법은 a) 삶은 팥분말 100중량부에 대하여 자일리톨 15 ~ 20중량부, 유산균분말 10 ~ 15중량부를 혼합하여 1차 혼합물을 얻는 제1단계와, b) 1차 혼합물 100중량부에 대하여 바나나과즙, 키위과즙 및 블루베리과즙이 중량비로 1:2:1로 혼합된 천연과즙 100 내지 150 중량부를 배합하여 2차 혼합물을 얻는 제2단계 및 c) 2차 혼합물을 과립화하고 건조 및 포장하는 제3단계를 포함하는 것으로 이루어진다.A method for producing an anti-thrombocyte activated granule-type red bean powder using natural juice and red bean powder comprises the steps of: a) mixing 15 to 20 parts by weight of xylitol, 100 parts by weight of lactic acid bacteria A first step of mixing 10 to 15 parts by weight of the powder to obtain a first mixture; b) mixing 100 parts by weight of the first mixture with a mixture of banana juice, kiwifruit juice and blueberry juice in a weight ratio of 1: 2: 100 to 150 parts by weight to obtain a second mixture, and c) granulating the second mixture, drying and packaging.
본 발명의 또 다른 목적달성을 위한 해결수단으로 천연과즙 및 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말로 이루어진 건강식품은 상기한 본 발명의 제1단계 내지 제4단계에 의해 제조된 과립형 팥분말을 포함하는 것으로 이루어진다.As a solution for achieving still another object of the present invention, a health food made of granular red bean powder enhanced in antithrombotic activity using natural fruit juice and red bean powder is prepared by mixing granular And red bean powder.
본 발명에 따른 상기 제1단계의 삶은 팥분말은 팥을 삶는 일반적인 방법에 따라 정선된 팥을 물에 불린(수침) 후, 물과 함께 팥이 충분히 익을 때까지 삶은 다음, 삶은 팥을 건조를 위하여 조분쇄하고, -80℃ ~ -30℃의 조건에서 함수율 2%로 동결건조한 후, 온도를 30℃까지 서서히 올려 건조된 삶은 팥을 분쇄기에서120 ~ 150메쉬로 분쇄하여 삶은 팥분말을 제조하는 것으로 이루어진다.The first stage boiled red bean powder according to the present invention is prepared by boiling the selected red beans in water according to the general method of boiling the red beans, boiling them with water until the beans are fully ripe, and then drying the boiled red beans Dried and lyophilized at a water content of 2% at a temperature of -80 ° C to -30 ° C and then gradually heated to 30 ° C to pulverize the dried boiled red beans in a grinder at 120-150 mesh to produce boiled red bean powder .
또는, 깨끗하게 세척한 팥을 50 ~ 80℃에서 3 ~ 5시간 볶은 후, 물과 함께 팥이 충분히 익을 때까지 삶은 다음, 삶은 팥을 상기한 방법으로 동결건조하여 얻어진 건조된 삶은 팥을 분쇄기에서 120 ~ 150메쉬로 분쇄하여 삶은 팥분말을 제조하는 것으로 이루어진다.Alternatively, the cleaned red beans are roasted at 50 to 80 ° C for 3 to 5 hours, then boiled with water until the red beans are sufficiently cooked, and then boiled red beans are lyophilized by the method described above. To 150 mesh to produce boiled red bean powder.
팥은 당질 54%, 사포닌(saponin) 0.3% 함유되어 있으며, 단백질은 21% 함유하며, 그 중 약 80%가 글로부린(globulin)이며, 지방은 적으나, 약 24%의 연지질이 함유되어 있는 것으로 밝혀져 있다. 상기 본 발명에 따른 동결건조한 삶은 팥분말은 100g당 356Kcal를 나타나며, 주요 영양성분의 함량을 아래 [표1] 및 [표2]에 나타내었다.The red bean contained 54% of carbohydrate and 0.3% of saponin. It contained 21% of protein, about 80% of which was globulin and the fat was low, but about 24% . The freeze-dried boiled red bean powder according to the present invention exhibits 356 Kcal per 100 g, and the contents of major nutrients are shown in [Table 1] and [Table 2] below.
또 본 발명에 따른 제1단계의 유산균분말은 락토바실러스 액시도필러스, 락토바실러스 불가리쿠스, 락토바실러스 프랜타럼, 비피도박테리움 비피덤, 비피도박테리움 락티스 등으로부터 선택되는 1 이상의 유산균분말로 이루어지며, 이러한 유산균분말은 시판되고 있으며, 예를 들면, (주)비전바이오캠사, 상품명 LLB 혼합유산균 509로 시판되며, 자일리톨 역시 널리 시판되고 있는 것을 사용하는 것으로 이루어진다.The first stage lactic acid bacteria powder according to the present invention may further comprise at least one lactobacillus powder selected from the group consisting of Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus frantarium, Bifidobacterium bifidum, Bifidobacterium lactis, These lactic acid bacteria powders are commercially available. For example, they are commercially available under the trade names Vision BioCampus, LLB mixed lactic acid bacteria 509, and xylitol, which are widely available.
상기 본 발명의 제2단계에 따른 바나나, 키위 및 블루베리에는 당, 식물섬유, 비타민 및 칼슘, 철분, 망간 등의 무기성분이 함유되어 있으므로 팥과 조합하여 팥에 부족한 영양성분을 조합하는 것으로 이루어지며, 시판하고 있는 바나나, 키위 및 블루베리를 이용하여 각각 믹서기로 분쇄하여 슬러리 상태로 하여 배합하거나 키위 및 블루베리를 함께 믹서기에 투입하고 분쇄하여 슬러리 상태로 하여 배합하는 것으로 이루어진다.Since the banana, kiwi and blueberry according to the second step of the present invention contain sugar, vegetable fiber, vitamins, and inorganic components such as calcium, iron, and manganese, they are combined with red bean And the mixture is pulverized with a mixer using a commercially available banana, kiwi and blueberry to form a slurry state, or the kiwi and blueberry are put into a mixer together and pulverized to prepare a slurry.
상기 바나나과즙, 키위과즙 및 블루베리과즙인 천연과즙의 배합은 상기 제1단계의 1차 혼합물과 교반하면서 균일하게 혼합하여 후속하는 제3단계에서 과립화가 잘 수행될 수 있는 반죽상태의 2차 혼합물을 얻는 것으로 이루어진다.The combination of the banana juice, the kiwifruit juice and the natural juice, which is the blueberry juice, is uniformly mixed while stirring with the first mixture of the first step, so that the second mixture in the kneading state which can be well granulated in the subsequent third step .
상기 본 발명의 반죽상태의 2차 혼합물의 과립화는 널리 알려진 과립제조기를 이용하여 과립으로 제조하며, 제조된 과립형 팥분말은 일반적으로 알려진 열풍건조기에 의해 열풍으로 건조한 후 포장하는 것으로 이루어진다. The granulation of the dough-state secondary mixture of the present invention is made into granules using a well-known granulating machine, and the granular red bean powder thus prepared is dried by hot air using a generally known hot air drier and then packed.
상기 본 발명의 제1단계 내지 제3단계로부터 제조된 과립형 팥분말은 동결건조한 삶은 팥의 경우 최대한 빨리 섭취해야 하는 결점을 개선하여, 과립형으로 가공함으로써 섭취가 간편하고, 팥에 천연과즙의 첨가에 의해 영양분 및 기호성이 개선되어 건강보조식품으로 유용하게 제공된다.The granular red bean powder prepared from the first step to the third step of the present invention improves deficiencies that should be taken as soon as possible in case of lyophilized boiled red beans and is processed into a granular form so that it is easy to ingest. The nutritional and palatability is improved by the addition, and it is usefully provided as a health supplement.
또한 일반적인 팥의 항당뇨 특성과 함께 본 발명에 따른 과립형 팥분말의 우수한 항혈전 활성으로 본 발명에 따른 과립형 팥분말은 심혈관계, 뇌혈관계 질환의 예방 및 개선에 유용한 건강보조식품 또는 의약 등으로 제공되는 것이 가능하다.In addition, the granular red bean powder according to the present invention has excellent antithrombotic activity of the granular red bean powder according to the present invention together with the general anti-diabetic characteristic of red bean of the present invention, and the granular red bean powder according to the present invention is useful as a health supplement or medicament useful for prevention and improvement of cardiovascular diseases and cerebrovascular diseases . ≪ / RTI >
본 발명의 천연과즙과 삶은 팥분말을 이용한 항혈전 활성 강화 과립형 팥분말은 동결건조한 삶은 팥분말을 과립으로 가공함으로써 삶은 팥의 경우 최대한 빨리 섭취해야 하는 결점을 개선함과 동시에 섭취가 간편한 특징이 있고 또 본 발명의 과립형 팥분말은 팥과 천연과즙의 영양성분의 조합 및 우수한 항혈전 활성을 나타내므로 일반적인 팥의 항당뇨 특성과 함께 심혈관계, 뇌혈관계 질환의 예방 및 개선에 유용한 건강보조식품으로 제공되는 특징을 지니고 있다.The anti-thrombocyte activated granule type red bean powder using the natural juice and boiled red bean powder of the present invention is characterized by processing the freeze-dried boiled red bean powder into granules, thereby improving deficiencies in the case of boiled red beans as soon as possible and at the same time, In addition, the granular red bean powder of the present invention exhibits a combination of nutritional components of red bean and natural fruit juice and exhibits excellent antithrombotic activity. Therefore, it is possible to provide a health supplement which is useful for prevention and improvement of cardiovascular and cerebrovascular diseases, As shown in FIG.
아래에서는 실시예(제조예) 및 시험예를 통하여 본 발명에 따른 천연과즙 및 팥분말을 이용한 항혈전 활성이 강화된 과립형 팥분말 및 그 제조방법에 대하여 보다 구체적으로 설명하지만 아래 기재에 의해 본 발명이 한정되는 것은 아니다.Hereinafter, the granular red bean powder enhanced in antithrombotic activity using the natural juice and red bean powder according to the present invention and the preparation method thereof will be described in more detail through Examples (Preparation Examples) and Test Examples, The invention is not limited thereto.
<실시예><Examples>
a). 삶은 팥분말 및 1차 혼합물 제조a). Manufacture of boiled bean powder and primary mixture
정선된 팥을 70℃ 조건에서 4시간 볶은 팥 100중량부에 대하여 물 150중량부 및 소량의 소금을 투입하고, 100℃ 조건에서 8시간 정도 끓이면서 팥을 충분히 익힌 다음, 삶은 팥을 미리 조분쇄하여 동결건조기에서 -45℃ 조건으로 4일간 건조시켜 함수율 2%의 동결건조하고, 얻어진 건조된 삶은 팥을 분쇄기로 150메쉬로 분쇄하여 삶은 팥분말을 제조하였다.150 parts by weight of water and a small amount of salt were added to 100 parts by weight of red bean roasted at 70 ° C for 4 hours and boiled for about 8 hours at 100 ° C to sufficiently cook red beans. Dried in a freeze dryer at -45 ° C for 4 days, and then dried at a moisture content of 2%. The resulting dried boiled red beans were pulverized with a grinder to a 150 mesh to produce boiled red bean powder.
상기 삶은 팥분말 100중량부에 대하여 자일리톨 20중량부 및 유산균분말(시판제품인(주)비전바이오캠사, 상품명 LLB 혼합유산균 509 사용) 15중량부의 비율로 교반기가 장착된 혼합기에 투입하고 균일하게 혼합하여 1차혼합물을 얻었다.20 parts by weight of xylitol and 15 parts by weight of a lactic acid bacterium powder (commercially available from Vision BioCampa Co., Ltd., trade name: LLB mixed lactic acid bacteria 509) were added to 100 parts by weight of the above boiled bean powder and mixed in a mixer equipped with a stirrer. A primary mixture was obtained.
b). 팥분말과 천연과즙의 혼합물 제조(2차 혼합물 제조)b). Preparation of a mixture of red bean powder and natural fruit juice (preparation of second mixture)
껍질을 제거한 바나나 및 키위, 블루베리를 중량비로 1 : 2 : 1의 비율이 되게 믹서기에 함께 투입하여 분쇄하여 슬러리 상태의 천연과즙을 얻었다.The peeled banana, kiwi, and blueberry were added together in a mixer at a weight ratio of 1: 2: 1, followed by pulverization to obtain a natural juice in a slurry state.
교반기가 장차가 된 배합기(반죽기)에 상기에서 제조한 1차 혼합물 100중량부에 대하여 상기 슬러리 상태의 천연과즙 100중량부를 천천히 투입하면서 1차 혼합물과 천연과즙이 골고루 배합되어 반죽상태가 되도록 하여 2차 혼합물을 얻었다.100 parts by weight of the slurry-like natural fruit juice was slowly added to 100 parts by weight of the primary mixture prepared in the above-mentioned mixer (kneader) in which the stirrer was introduced, so that the primary mixture and the natural fruit juice were uniformly mixed, Tea mixture.
c). 과립제조 및 건조(최종목적물)c). Granulation and drying (final object)
상기에서 제조한 반죽상태의 2차 혼합물을 과립제조기에 넣고 과립으로 한 다음, 열풍건조기에 넣고, 50℃에서 24시간 건조하여 건조된 팥과립을 제조하였다.The kneaded secondary mixture prepared above was placed in a granulator and granulated. The granules were then placed in a hot-air dryer and dried at 50 ° C for 24 hours to prepare dried bean granules.
<시험예 1>≪ Test Example 1 >
상기 실시예에서 제조한 팥과립은 pH 4.09, 당도 80(Brix)를 나타내는 것을 확인할 수 있었으며, 이러한 본 발명의 팥과립은 일반적인 팥가루가 통상 pH 6.15, 당도 40(Brix)를 나타내는데 비하여, pH는 낮고, 당도가 높게 나타났으며, 이는 자일리톨 및 천연과즙의 유기산의 첨가에 기인하는 것으로 예측된다.The red bean granules prepared in the above example exhibited a pH of 4.09 and a sugar content of 80 (Brix). The red bean flour of the present invention generally showed a pH of 6.15 and a sugar content of 40 (Brix) And high sugar content, which is predicted to be due to the addition of organic acids of xylitol and natural fruit juice.
그리고 상기 실시예에서 제조한 팥과립에 대하여, 조직감, 향기, 기호성에 관한 관능평가를 위해 성인남녀 각 10명씩을 대상으로 하여 평가하고 그 결과를 아래 [표 3]에 나타내었다(평가방법은 10(아주좋음) ~ 0(아주나쁨)으로 실시하고 평균점수로 나타내었다).For the sensory evaluation on texture, flavor and palatability of the red bean granules prepared in the above example, each adult male and female was evaluated for each 10 persons, and the results are shown in Table 3 below (the evaluation method is 10 (Very good) ~ 0 (very bad) and expressed as average score.
<시험예 2>≪ Test Example 2 &
상기 실시예에서 제조한 팥분말 및 팥과립에 대한 에탄올 추출효율 및 성분을 비교하고, 그 결과를 아래 [표 4]에 나타내었으며, 추출방법은 각각의 시료에 10배 Volume으로 95% Ethanol을 첨가하여 2회 추출하였다.The ethanol extraction efficiency and components of the red bean powder and red bean granules prepared in the above examples were compared and the results are shown in Table 4 below. The extraction method was as follows: 95% Ethanol was added to each sample 10 times in volume And extracted twice.
또한 Hexene분획 , Ethyl acetate 분획 , Butanol 분획 및 물 잔류물의 분획효율을 분석하고, 그 결과를 아래 [표 5]에 나타내었다.The fractions of Hexene fraction, Ethyl acetate fraction, Butanol fraction and Water residue were analyzed, and the results are shown in Table 5 below.
상기 [표 4]에 의하면, 팥분말는 1차와 2차 추출을 통해 1.83%의 에탄올 추출 효율을 보이고 있으며, 이에 비해 팥과립의 에탄올 추출효율은 20.15%를 나타내고 있는 점으로 미루어 본 발명에 따른 팥과립이 팥분말에 비해 약 11배 이상 높은 지용성 성분을 가지고 있음을 알 수 있으며, 아래 [표 5]에 의하면, 팥분말에서 15%가 Hexene 분획물인데 비하여, 팥과립의 경우 대부분(87%)이 헥센분획물로 이행된 점을 미루어 팥의 경우 헥센추출성 물질이 0.27g/팥 100g 인데 비해, 팥과립의 경우 헥센 추출성 물질이 17.4g/팥과립 100g 인 것을 확인할 수가 있다.According to the above Table 4, the extraction efficiency of 1.83% of red bean powder by primary and secondary extraction is 20.15% compared with that of red bean powder, As shown in Table 5 below, 15% of Hexene fraction is in the red bean powder compared to that of red bean powder, whereas most of the red bean powder is 87% In the case of red bean, the content of hexene extractable material is 0.27 g / red bean 100 g, whereas that of red bean granule is 17.4 g / red bean granule 100 g.
<시험예 3>≪ Test Example 3 >
상기 실시예에서 제조한 팥가루 및 팥과립의 에탄올 추출물과 Hexene 분획, Ethyl acetate 분획, Butanol 분회 및 물 잔류물에 대하여 총 당과 환원당, 총 폴리페놀 및 총 플라보노이드에 대한 성분을 분석하고 그 결과를 아래 [표 6]에 나타내었다.The components of total sugar and reducing sugar, total polyphenol and total flavonoid were analyzed for the ethanol extracts of red bean flour and red bean flour, Hexene fraction, Ethyl acetate fraction, Butanol fraction and water residues prepared in the above Examples, Are shown in Table 6 below.
1). 총 당 및 환원당 정량One). Quantity of total sugar and reducing sugar
환원당은 DNS법으로 정량하고, 총당은 phenol-sulfuric acid법을 이용하여 정량하였으며, 자세하게는 환원당 분석은 Dinitrosalicylic acid(DNS)법을 응용하여 전 처리된 시료에 25% HCl을 넣고 60℃에서 30분간 가수분해한 뒤 다시 8N NaOH로 중화하고 여기에 DNS시약을 넣어 반응시킨 후, 550nm에서 흡광도를 측정하였다. Reducing sugar was quantitated by DNS method and total sugar was quantified by phenol-sulfuric acid method. Specifically, 25% HCl was added to pretreated sample using dinitrosalicylic acid (DNS) method for reducing sugar analysis. After hydrolysis, it was neutralized with 8N NaOH, reacted with a DNS reagent, and absorbance was measured at 550 nm.
2)총 폴리페놀 정량2) Total polyphenol content
팥분말 및 팥과립의 총 polyphenol 함량은 추출 검액 400㎕에 50㎕의 Folin-ciocalteau, 100㎕의 Na2CO3포화용액을 넣고 실온에서 1시간 방치한 후 725 nm에서 흡광도를 측정하였다. 표준시약으로는 tannic acid를 사용하였다. Total polyphenol contents of red bean powder and red bean granules were measured by adding 50 μl of Folin-ciocalteau and 100 μl of Na 2 CO 3 saturated solution to 400 μl of the extract solution, leaving the solution at room temperature for 1 hour, and then measuring the absorbance at 725 nm. Tannic acid was used as a standard reagent.
3)총 플라보노이드 정량3) Quantification of total flavonoids
팥분말 및 팥과립의 총 flavonoid의 함량 측정은 각각의 시료를 18시간 메탄올 교반 추출하고 여과한 추출 검액 400㎕에 90% diethylene glycol 4㎖를 첨가하고 다시 1N NaOH 40㎕를 넣고 37℃에서 1시간 반응 후 420nm에서 흡광도를 측정하였다. 표준시약으로는 rutin을 사용하였다. To measure the total flavonoid content in red bean powder and red bean granules, each sample was stirred for 18 hours in methanol, and 4 ml of 90% diethylene glycol was added to 400 μl of the filtered extract. 40 μl of 1N NaOH was added thereto, Absorbance was measured at 420 nm after the reaction. As a standard reagent, rutin was used.
시료
sample
추출 및 분획효율
(%)
Extraction and fractionation efficiency
(%)
(Rutin Eq.)TF
(Routine Eq.)
(Tannic acid
Eq.)TP
(Tannic acid
Eq.)
(Sucrose Eq.)TS
(Sucrose Eq.)
(Glucose Eq.)RS
(Glucose Eq.)
팥
분
말
red bean
minute
Words
팥
과
립
red bean
and
Lip
상기 [표 6]에 의하면, 팥분말 및 팥과립 에탄올 추출물을 비교해 보았을 때, 총 폴리페놀 함량은 팥가루에서 2배 정도 높게 나타났으나, 반면 총 당의 경우에는 팥 과립에서 3배 높게 나타났으며, 또한 환원당의 경우 팥과립이 팥분말 보다 약 7.7배 높은 함량을 나타내어 팥과립 추출물이 상대적으로 많은 양의 당질을 포함하고 있음을 확인할 수 있었다.According to the above Table 6, when the ethanol extracts of red bean powder and red bean powder were compared, the total polyphenol content was about twice as high as that of red bean powder, whereas that of total sugar was three times as high as that of red bean powder , And in the case of reducing sugar, the content of red bean granules was about 7.7 times higher than that of red bean powder, indicating that the red bean granule extract contained a relatively large amount of saccharides.
그리고 순차적 유기용매 분획물의 경우, 총 폴리페놀 함량은 팥분말 및 팥과립 에서 모두 에틸아세테이트 분획 > 부탄올 분획 > 헥센 분획 > 물 잔류물 순으로 나타났으나, 총 플라보노이드 함량은 팥분말의 경우, 에틸아세테이트 분획 > 부탄올 분획 > 헥센 분획 > 물 잔류물 순으로, 팥 과립의 경우 에틸아세테이트 분획 > 헥센 분획 > 물 잔류물 > 부탄올 분획 순으로 나타났다. In the case of sequential organic solvent fractions, the total polyphenol contents were in the order of ethyl acetate fraction, butanol fraction, hexene fraction and water residue in the red bean powder and red bean powder, respectively. The total flavonoid content, however, The fractions were in the order of ethyl acetate fraction, hexane fraction, water residue, and butanol fraction in the order of fraction> butanol fraction> hexene fraction> water residue.
<시험예 4><Test Example 4>
상기 팥분말 및 팥과립의 에탄올 추출물과 Hexene 분획, Ethyl acetate 분획, Butanol 분획 및 물 잔류물에 대한 항혈전 활성평가를 하고, 그 결과를 아래 [표7]에 나타내었다. 항혈전 활성평가는 기존에 보고된 방법에 준해 평가하였으며(Sohn et al., 2004. Kor. J. Pharmacogn 35. 52-61; Kwon et al., 2004. J. Life Science, 14. 509-513; 류 등 2010. J. Life Science, 20. 922-928), 트롬빈 타임, 프로트롬빈 타임과 에이피티 타임을 측정하였다. 혈장은 표준혈장(MD Pacific Co., China)을 구입하여 사용하였으며, 기타 시약은 씨그마사(Sigma Co., USA)의 제품을 구입하여 사용하였다. 트롬빈 타임, 프로트롬빈 타임과 에이피티 측정법은 다음과 같은 과정으로 수행되었다.The antithrombotic activity of the ethanol extract of red bean powder and red bean granules, Hexene fraction, Ethyl acetate fraction, Butanol fraction and water residue was evaluated, and the results are shown in Table 7 below. Evaluation of antithrombotic activity was evaluated in accordance with previously reported methods (Sohn et al., 2004. Kor J. Pharmacogn 35, 52-61; Kwon et al., 2004. J. Life Science, 14. 509-513 ; 2010. J. Life Science, 20. 922-928), thrombin time, prothrombin time and apathy time were measured. Plasma was purchased from standard plasma (MD Pacific Co., China) and other reagents were purchased from Sigma Co., USA. The thrombin time, prothrombin time, and apathy measurements were performed as follows.
a). 트롬빈 타임(Thrombin Time)a). Thrombin Time
37℃에서 0.5U 트롬빈 (Sigma Co., USA) 50㎕와 20mM CaCl2 50㎕, 다양한 농도의 시료 추출액 10㎕를 Amelung coagulometer KC-1A(Japan)의 튜브에 혼합하여 2분간 반응시킨 후, 혈장 100㎕를 첨가한 후, 혈장이 응고될 때까지의 시간을 측정하였다. 대조로는 아스피린(Sigma Co., USA)을 사용하였으며, 용매 대조구로는 시료 대신 DMSO를 사용하였다. DMSO의 경우 32.1초의 응고시간을 나타내었다. 0.5U thrombin in 37 ℃ (Sigma Co., USA) 50㎕ with 20mM CaCl 2 And 10 μl of sample extracts at various concentrations were mixed in a tube of Amelung coagulometer KC-1A (Japan) and reacted for 2 minutes. Then, 100 μl of plasma was added, and the time until the plasma was solidified was measured. As a control, aspirin (Sigma Co., USA) was used and DMSO was used as a solvent control instead of the sample. DMSO showed a clotting time of 32.1 sec.
트롬빈 저해 효과는 3회 이상 반복한 실험의 평균치로 나타내었으며, 시료 첨가 시의 응고시간을 용매 대조구의 응고시간으로 나눈 값으로 나타내었다.The thrombin inhibitory effect was expressed as the average value of the experiments repeated three times or more, and the coagulation time at the time of adding the sample was divided by the coagulation time of the solvent control.
b). 프로트롬빈 타임(prothrombin time)b). Prothrombin time
표준혈장(MD Pacific Co., China) 70㎕와 다양한 농도의 시료액 10㎕를 Amelung coagulometer KC-1A(Japan)의 튜브에 첨가하여 37℃에서 3분간 가온 후, 130㎕의 PT reagent를 첨가하고 혈장이 응고될 때까지의 시간을 3회 반복한 실험의 평균치로 나타내었다. 대조로는 아스피린(Sigma Co., USA)을 사용하였으며, 용매 대조구로는 시료 대신 DMSO를 사용하였다. DMSO의 경우 18.1초의 응고시간을 나타내었다.70 μl of standard plasma (MD Pacific Co., China) and 10 μl of various concentrations of sample were added to a tube of Amelung coagulometer KC-1A (Japan), and the mixture was heated at 37 ° C. for 3 minutes. Then, 130 μl of PT reagent was added The time until the plasma coagulated was expressed as the average value of the experiment which was repeated three times. As a control, aspirin (Sigma Co., USA) was used and DMSO was used as a solvent control instead of the sample. DMSO showed a clotting time of 18.1 sec.
프로트롬빈 저해 효과는 3회 이상 반복한 실험의 평균치로 나타내었으며, 시료 첨가 시의 응고시간을 용매 대조구의 응고시간으로 나눈 값으로 나타내었다.The prothrombin inhibitory effect was expressed as the average value of the experiment repeated three times or more, and the solidification time at the time of adding the sample was divided by the solidification time of the solvent control.
c). aPTT (activated Partial Thromboplastin Time) c). aPTT (activated Partial Thromboplastin Time)
혈장100μl와 다양한 농도의 시료 추출액 10㎕를 Amelung coagulometer KC-1A(Japan)의 튜브에 첨가하여 37℃에서 3분간 가온한 후, 50㎕의 aPTT reagent(Sigma, ALEXINTM)를 첨가하고 다시 37℃에서 3분간 배양하였다. 이후 50㎕ CaCl2(35mM)을 첨가한 후 혈장이 응고될 때까지의 시간을 측정하였다. 용매 대조구로는 시료 대신 DMSO를 사용하였으며, 이 경우 55.1초의 응고시간을 나타내었다. aPTT의 결과는 3회 반복한 실험의 평균치로 나타내었으며, 시료 첨가시의 응고시간을 용매 대조구의 응고시간으로 나눈 값으로 나타내었다.Add 50 μl of aPTT reagent (Sigma, ALEXIN ™ ) to the tubes of Amelung coagulometer KC-1A (Japan) and incubate at 37 ° C for 3 minutes. For 3 minutes. Then, 50 Ca CaCl 2 (35 mM) was added and the time until the plasma was solidified was measured. As the solvent control, DMSO was used instead of the sample. In this case, the solidification time was 55.1 seconds. The results of aPTT were expressed as the average value of three replicate experiments, and the solidification time at the time of sample addition was expressed as the value divided by the solidification time of the solvent control.
(㎎/㎖)Conc
(Mg / ml)
팥분말
Red bean powder
팥과립
Red bean granules
EA fr.
EA fr.
상기 [표 7]에 나탄 바와 같이 팥분말과는 달리 팥과립의 Hexene 및 Ethyl acetate 분획물에서 매우 강력한 내인성 혈액응고에 대한 저해활성을 확인할 수 있으며, 또 혈액응고 저해활성이 Aspirin보다 더 우수한 것을 확인할 수 있는 점을 미루어 볼 때, 본 발명에 따른 팥과립 제품은 내인성 혈액응고의 저해를 통한 항혈전 활성을 나타내어 다양한 심혈관계, 뇌혈관계 질환의 예방 및 개선에 기여할 것을 쉽게 예측할 수가 있다.As shown in Table 7, unlike the red bean powder, Hexene and Ethyl acetate fractions of red bean granules showed very strong inhibitory activity against endogenous blood coagulation, and the coagulation inhibition activity of blood was better than that of Aspirin The red bean granular product according to the present invention exhibits anti-thrombotic activity through inhibition of endogenous blood coagulation, so that it can be easily predicted to contribute to prevention and improvement of various cardiovascular and cerebrovascular diseases.
Claims (8)
b). 1차 혼합물 100중량부에 대하여 바나나과즙, 키위과즙 및 블루베리과즙이 중량비로 1:2:1로 혼합된 천연과즙 100 내지 150 중량부를 배합하여 2차 혼합물을 얻는 제2단계 및
c). 2차 혼합물을 과립화하여 건조하는 제3단계를 포함하는 것을 특징으로 하는 팥분말 및 천연과즙을 이용한 항혈전 활성 강화 과립형 팥분말의 제조방법.a). The boiled bean is prepared by mixing 15 to 20 parts by weight of xylitol, 100 parts by weight of red bean powder, 1 part selected from Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus frantarium, Bifidobacterium bifidum and Bifidobacterium lactis And 10 to 15 parts by weight of the lactic acid bacterium powder is mixed to obtain a first mixture,
b). A second step of blending 100 to 150 parts by weight of natural juice mixed with 1: 2: 1 by weight of banana juice, kiwifruit juice and blueberry juice in a weight ratio of 100 parts by weight of the first mixture, and
c). And a third step of granulating and drying the second mixture. The method for producing granular red bean powder having enhanced antithrombotic activity using red bean powder and natural fruit juice.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140019506A KR101590858B1 (en) | 2014-02-20 | 2014-02-20 | Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140019506A KR101590858B1 (en) | 2014-02-20 | 2014-02-20 | Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150098351A KR20150098351A (en) | 2015-08-28 |
KR101590858B1 true KR101590858B1 (en) | 2016-02-04 |
Family
ID=54059795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140019506A KR101590858B1 (en) | 2014-02-20 | 2014-02-20 | Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101590858B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180073193A (en) | 2016-12-22 | 2018-07-02 | 김해용 | manufacturing method of adzuki bean powder |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101227061B1 (en) | 2011-04-13 | 2013-02-04 | 박정아 | The manufacturing method of red-bean powder |
-
2014
- 2014-02-20 KR KR1020140019506A patent/KR101590858B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101227061B1 (en) | 2011-04-13 | 2013-02-04 | 박정아 | The manufacturing method of red-bean powder |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180073193A (en) | 2016-12-22 | 2018-07-02 | 김해용 | manufacturing method of adzuki bean powder |
Also Published As
Publication number | Publication date |
---|---|
KR20150098351A (en) | 2015-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104663996B (en) | Coffee substitute and preparation method thereof | |
KR20140103622A (en) | The method for manufacturing functional tea product made from onion skin, and the product made by the method | |
KR100878876B1 (en) | Process for Preparing Granule using Rubi Fructus | |
KR101969202B1 (en) | Manufacturing method of corn bread | |
KR20160092631A (en) | The manufacturing method of aronia powder food and the product | |
KR102002080B1 (en) | Method for producing glutinous rice cake using persimmon, grain and medicinal plant | |
KR101590858B1 (en) | Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof | |
KR101708553B1 (en) | Manufacturing method for red bean jello using the percolate and dried powder of phaseolus radiatus l and the red bean jello manufactured by the same | |
KR20150055883A (en) | Soybean Paste Using Dangjo Pepper Seed and Stachys sieboldii Miq. Root and Manufacturing Method Thereof | |
KR102453819B1 (en) | Method for manufacturing beverages using starch-containing crops | |
KR101837067B1 (en) | A method for preparing an extract or the powder of steamed Dendropanax morbifera showing abundant total chlorophyll component and quercetin component and the health functional food comprising the an extract or the powder prepared thereby | |
KR20050038603A (en) | Noodles, Cheonma, Noodles, Powdered Noodles, Sujebi, Dumplings, Rice Cakes, Confectionery | |
KR101947013B1 (en) | Pudding comprising aronia, Cudrania tricuspidata and blueberry extract and preparation method thereof | |
KR20170107936A (en) | A method for preparing an extract or the powder of non-steamed Dendropanax morbifera showing abundant total chlorophyll component and quercetin component and the health functional food comprising the an extract or the powder prepared thereby | |
KR20140089124A (en) | Jam comprising rice grain syrup and Manufacturing method thereof | |
KR101559954B1 (en) | Composition for Retarding Aging of Rice Cake Containing Cashew Powder | |
KR101164930B1 (en) | Preparation method of soybean curd comprising sorghum with reinforced tannin and dietary fiber | |
KR101402600B1 (en) | Instant noodle manufacturing methods | |
KR20210119221A (en) | Enforced Antithrombosis activity, granule-type azuki bean powder containing Natural fruit juice and manufacturing Method thereof | |
KR102672335B1 (en) | Functional red bean porridge having the activities of antioxidation, antidiabetes and antithrombosis comprising hempseed, beta vulgaris, walnut and almond | |
KR20150120038A (en) | health assistance food having fermented soybeans improved flavor and manufacturing method thereof | |
KR101526876B1 (en) | New method for producing Acanthopanax leaves extract and Acanthopanax leaves extract produced by the same method | |
KR102431231B1 (en) | Functional rice cake comprising vitamins and method of manufacturing the same | |
KR20180077106A (en) | A composition for improving memory or cognitive function comprising a aurantii fructus immaturus supercritical extract as an active ingredient | |
KR101793931B1 (en) | Manufacturing Method of Improved Red Bean Doenjang |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
LAPS | Lapse due to unpaid annual fee |